Actavis President & CEO Brent Saunders explains the new corporate name, and the strong earnings beat. "We keep surprising people," says Saunders.
David Pyott, Allergan chairman & CEO, discusses the company's historic quarter, Bill Ackman's failed attempt to take over the company and the decision to subdivide the management team.
Valeant CEO Mike Pearson tells CNBC's Meg Tirrell the company is on a mission to prove allegations against the business model are not true. Pearson says Valeant is unlikely to work with Bill Ackman.
CNBC's Kate Kelly reveals what investors can expect from hedge funds and activists in 2015.